Roivant Sciences Ltd.
NASDAQROIV enters the final stretch of September with an intriguing disconnect: analysts have been busy raising targets while the stock slips, closing Tuesday at $38.22 — down 3.2% on the week despite a 5.3% gain over the past month. The analyst story is the most notable angle this week. Five firms raised price targets in a fourteen-day window, and none cut. Stifel initiated coverage…
ROIV put-call ratio plunges to 0.48, lowest in 52 weeks, signaling bullish options positioning as stock trades near analyst targets.
ROIV enters the final stretch of September with an intriguing disconnect: analysts have been busy raising targets while the stock slips, closing Tuesday at $38.22 — down 3.2% on the week despite a 5.3% gain over the…
Roivant Sciences arrives at its May 29 earnings report with the short thesis visibly retreating and the analyst community moving in one direction: up. The most striking shift since the last note is the reversal in…
Snapshot as of 4 Oct 2026
Roivant Sciences heads into a pivotal stretch — earnings due May 29 — with short sellers rebuilding positions, executives selling stock, and options traders the most bullish they've been in months. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ROIV — free to start on ORTEX.
Sign up for free →Open ROIV on ORTEX